ClinConnect ClinConnect Logo
Search / Trial NCT05746520

Complex And Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure (CASA RELAX) - Atrium Health

Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Feb 16, 2023

Trial Information

Current as of July 12, 2025

Recruiting

Keywords

Post Operative Antibiotics Acute Appendicitis Complicated Appendicitis

ClinConnect Summary

The CASA RELAX clinical trial is exploring how effective and safe it is to use a shorter course of antibiotics after surgery for appendicitis, which is an inflammation of the appendix. The study aims to find out if patients who have either simple or complicated appendicitis can safely recover with less antibiotic treatment while still preventing infections. This trial is currently looking for participants aged 18 and older who will be undergoing an appendectomy (surgery to remove the appendix) and who can provide informed consent.

If you participate in this trial, you will receive either the standard antibiotic treatment or a shorter course after your surgery. The researchers want to see how well this works and if it leads to fewer complications. To be eligible, you need to be generally healthy enough for surgery and able to communicate with the medical team after you leave the hospital. However, certain individuals, such as those with specific health issues or who are pregnant, may not be able to join. This study is an important step in understanding how to make recovery from appendicitis surgery safer and more efficient.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 years
  • Planned appendectomy (laparoscopic or open)
  • Willing and able to provide informed consent
  • Working telephone number or reliable method to contact patient after hospital discharge
  • Exclusion Criteria:
  • Unable to consent
  • Pregnant Women
  • Prisoners
  • immunocompromised as determined by clinical team, or patients actively receiving steroids, chemotherapy, or immunosuppressing medications (for example tacrolimus), or patients with active hematologic malignancy affecting the immune system, leukopenia, or end-stage Acquired immunodeficiency syndrome (AIDS)
  • Heart Failure
  • Allergy to Bupivacaine
  • Unlikely to comply with treatment or follow-up
  • Inpatient consultation for appendicitis
  • Clinically suspected sepsis based on Sepsis-3 definition
  • Current use of antibiotics for other indications
  • Type 1 Diabetes or uncontrolled hyperglycemia

About Wake Forest University Health Sciences

Wake Forest University Health Sciences is a leading academic research institution dedicated to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on multidisciplinary collaboration, the organization leverages its extensive expertise in medical research, patient care, and education to develop and evaluate new therapies and interventions. Committed to improving patient outcomes and public health, Wake Forest University Health Sciences fosters a dynamic environment for scientific inquiry, engaging in a wide range of clinical studies that address pressing health challenges. Through its rigorous methodologies and ethical standards, the institution aims to contribute significantly to the medical field and enhance the quality of life for diverse populations.

Locations

Winston Salem, North Carolina, United States

Patients applied

0 patients applied

Trial Officials

Rafael Torres Fajardo, MD

Principal Investigator

Wake Forest University Health Sciences

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials